Households in Britain with a user of GLP-1 drugs are spending £1bn ($1.31bn) less on grocery products, data suggests.
Research by Worldpanel by Numerator also indicates there are 2.6 million adults in Britain using the weight-loss medication.
The study, Worldpanel’s fourth, was carried out in August and took in more than 9,600 households.
A poll the researchers conducted in June estimated GLP-1 users were spending £780m less on groceries. The latest survey indicates the impact is now more than £1bn.
Chantel Kennaugh, head of public sector and nutrition at Worldpanel, said: “Too often, the GLP-1 impact is framed as a story about value or volume decline but there’s a much more interesting story sitting behind this. From a grocery perspective, this new audience is being more mindful about what and how they eat.”
The researchers said impulse and indulgence products had been most affected. The amount GLP-1 users spend on crisps has fallen 15%, the data shows. Expenditure on alcohol has fallen by the same amount.
Volume sales of frozen ready meals have jumped 30%, while unit sales of hot chocolate and malt drinks has grown 16%.
Worldpanel said some spending is being redirected to other sectors. The firm said GLP-1 users spent £78m more than expected on health and beauty products in the first year after they started taking the medication.
The researchers estimate 8.5% of households in Britain contain a GLP-1 user, which amounts to the number of vegetarians and pescatarians combined.
Kennaugh added: “Our estimates suggest that GLP-1 usage is set to surpass 10% of GB households in 2027. This is not a flash-in-the-pan trend but a seismic change that requires retailers and manufacturers to re-think their strategies.”
On the other side of the Atlantic, research by Tesco-owned customer data firm Dunnhumby has suggested GLP-1 drugs are influencing what more than one in five adults across the Americas eat and drink.
After surveying 8,500 consumers across six countries in August, Dunnhumby said each GLP-1 user shapes the dietary habits of an average of 2.08 people within their household.
Across the six markets in the Americas surveyed – the US, Canada, Mexico, Brazil, Colombia, and Chile – 10.2% of adults have used a GLP-1 medication, while 21.3% say their food and drink choices are shaped by the drugs.


